• LIVING WITH CRC

    Study identifies risk factors for irinotecan liver toxicity

    A retrospective study of 229 cancer patients receiving irinotecan chemotherapy identified key risk factors for hepatotoxicity, which could help clinicians monitor and manage this side effect more effectively. (Frontiers in Oncology)